Cryo Cell International (CCEL) investor relations material

Executive summary

• Revenue for the quarter ended February 28, 2026, was $7.68 million, down from $7.97 million in Q1 2025, mainly due to a decrease in new domestic cord blood specimens processed and lower public cord blood banking revenue.

• Net income for the quarter was $47,108 ($0.01 per share), a significant decrease from $282,855 ($0.03 per share) in the prior year period, primarily due to higher legal expenses related to the Duke University dispute.

• The company is engaged in arbitration with Duke University over a terminated license agreement, impacting expansion plans and resulting in increased legal costs.

• The company continues to lead in private cord blood banking and operates both private and public banking programs.

Financial highlights

• Processing and storage fees were $7.64 million, down from $7.87 million year-over-year, reflecting a 3% decrease in recurring annual storage fees and a 16% drop in new specimens processed.

• Product revenue increased to $38,594 from $20,913, while public cord blood banking revenue dropped sharply to $1,410 from $82,079.

• Cost of sales decreased 17% to $1.66 million, while selling, general, and administrative expenses rose 8% to $5.01 million, mainly due to legal fees.

• Operating income was $765,134, down from $1.06 million year-over-year.

• Cash and cash equivalents at quarter-end were $249,672, down from $319,031 at the start of the quarter.

Outlook and guidance

• The company does not anticipate further investments in activities related to the Duke License Agreement until the dispute is resolved.

• Cash flows from operations, marketable securities, and external capital are expected to be sufficient for at least the next 12 months, but future capital needs depend on the Duke arbitration outcome.